Cancer Biopsy
Cancer Biopsy Market by Product (Instruments, Kits & Consumables, Services), Type (Liquid Biopsies, Tissue Biopsies), Indication - Global Forecast 2024-2030
360iResearch Analyst
SPEAK TO ANALYST? OR FACE-TO-FACE MEETING?
Want to know more about the cancer biopsy market or any specific requirement? Ketan helps you find what you're looking for.
DOWNLOAD A FREE PDF
This free PDF includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.

[186 Pages Report] The Cancer Biopsy Market size was estimated at USD 29.84 billion in 2023 and expected to reach USD 33.48 billion in 2024, at a CAGR 12.28% to reach USD 67.14 billion by 2030.

Cancer Biopsy Market
To learn more about this report, request a free PDF copy
Cancer biopsies involve extracting tissue samples for diagnostic analysis and are essential in oncology for accurately diagnosing and characterizing tumors. These procedures guide effective treatment strategies, with methods such as needle biopsies, surgical biopsies, and imaging-guided biopsies being commonly used. Biopsies are crucial for precise tumor profiling, enabling personalized treatment plans and their relevance expands across various cancer types, including skin, breast, lung, prostate, and colorectal cancers. The primary end users, such as hospitals, diagnostic laboratories, and cancer research institutes, utilize biopsies for patient care and clinical research. Key growth drivers include technological advancements, the growing focus on personalized medicine, and government funding. Significant opportunities lie in adopting liquid biopsies, integrating artificial intelligence (AI) for image analysis, expanding into developing regions with rising healthcare investments, and forming collaborations with technology firms and healthcare providers. Challenges include high costs, a shortage of skilled technicians, stringent regulatory standards, and ethical concerns regarding invasive procedures. Innovation areas encompass biomarker discovery, minimally invasive techniques, genomic integration, and point-of-care diagnostics.
Regional Insights
The cancer biopsy market exhibits strong activity across different geographies, with distinct dynamics observed in each region. The United States is a key nation due to its advanced healthcare infrastructure, high adoption of cutting-edge biopsy technologies, and significant investments in cancer research. In Europe, countries such as Germany, France, and the UK maintain their leadership in healthcare technologies, emphasizing early cancer detection and personalized medicine. The Middle East is investing heavily in improving healthcare outcomes with minimally invasive biopsy techniques, while Africa is focusing on enhancing diagnostic capabilities and access to treatment. Germany, a leading exporter of advanced biopsy technologies, and China, with its rapidly expanding manufacturing base, also contribute prominently to global trade. Japan and India are pivotal, given their technological innovations and growing participation in the international trade of medical devices. In the Asia-Pacific region, the need for advanced diagnostic services is rising due to increasing cancer cases and improving healthcare infrastructure. Recent developments include significant research in biomarker identification, new patents focusing on non-invasive biopsy techniques, and substantial investments in R&D. Decision-makers should invest in emerging technologies, expand market reach, engage in collaborative R&D, and ensure regulatory compliance to capitalize on the growing cancer biopsy market. The cancer biopsy market is under stringent regulatory frameworks across major regions. In the United States, the Food and Drug Administration (FDA) and Clinical Laboratory Improvement Amendments (CLIA) ensure quality and reliable diagnostic methods. European Union (EU) policies such as CE marking and In Vitro Diagnostic Regulation (IVDR) enforce safety and medical standards. In China, the National Medical Products Administration (NMPA) mandates rigorous testing, while compliance with Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) maintains quality. Vendors are creating compliance teams, developing adaptive frameworks, and prioritizing ethical clinical trials to meet these regulations. Manufacturers in developed countries should invest in genomics and non-invasive methods. Collaborations with technology firms, forming strategic alliances in emerging markets, and integrating advanced diagnostics into healthcare systems are essential for growth. Larger economies can capitalize through infrastructure improvements, government support, public-private partnerships, and patient awareness campaigns. Noteworthy industry events for 2023-2024 include FDA approvals of blood-based biopsies, mergers within leading biotech firms, global oncology conferences, AI integration in diagnostics, and the expansion of telehealth services. These strategic moves can drive innovation, inform regulatory readiness, and enhance market penetration, contributing to better cancer diagnosis and patient outcomes.
Market Dynamics

The market dynamics represent an ever-changing landscape of the Cancer Biopsy Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

  • Market Drivers
    • Increasing preference for non-invasive procedures
    • Emerging significance of cancer biopsies and tissue sectioning
    • Growing adoption of liquid cancer biopsies
  • Market Restraints
    • Low sensitivity and specificity of cancer biopsies
  • Market Opportunities
    • Technological advancements in cancer biopsy devices
    • Increasing R&D activities for novel cancer treatments
  • Market Challenges
    • Stringent regulatory requirements and unclear reimbursement scenarios
Market Disruption Analysis

The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Cancer Biopsy Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Cancer Biopsy Market.

Porter’s Five Forces Analysis

The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Cancer Biopsy Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.

Value Chain & Critical Path Analysis

The value chain of the Cancer Biopsy Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.

Pricing Analysis

The pricing analysis comprehensively evaluates how a product or service is priced within the Cancer Biopsy Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Cancer Biopsy Market.

Technology Analysis

The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Cancer Biopsy Market.

Patent Analysis

The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Cancer Biopsy Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.

Trade Analysis

The trade analysis of the Cancer Biopsy Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.

Regulatory Framework Analysis

The regulatory framework analysis for the Cancer Biopsy Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cancer Biopsy Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cancer Biopsy Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cancer Biopsy Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Cancer Biopsy Market, highlighting leading vendors and their innovative profiles. These include Agena Bioscience, Inc., Agilent Technologies Inc., ANGLE PLC, Becton, Dickinson and Company, BIOCEPT, Inc., Danaher Corporation, Epigenomics AG, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Freenome Holdings, Inc., GRAIL, Inc., Guardant Health, HelioHealth, Hologic, Inc., Illumina, Inc., Laboratory Corporation of America Holdings, Lucence Health Inc., MDx Health, Myriad Genetics, Inc., Natera, Inc., OncoCyte Corp, Personalis Inc., QIAGEN N.V., Thermo Fisher Scientific, Inc., and Trovagene, Inc.

Cancer Biopsy Market - Global Forecast 2024-2030
To learn more about this report, request a free PDF copy
Market Segmentation & Coverage

This research report categorizes the Cancer Biopsy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Instruments
    • Kits & Consumables
    • Services
  • Type
    • Liquid Biopsies
    • Tissue Biopsies
      • Needle Biopsies
        • Core Needle Biopsy
        • Fine Needle Aspiration
      • Surgical Biopsies
  • Indication
    • Blood Cancers
    • Breast Cancer
    • Cervical Cancers
    • Colorectal Cancer
    • Kidney Cancers
    • Liver Cancers
    • Lung Cancers
    • Ovarian Cancers
    • Pancreatic Cancers
    • Prostate Cancers
    • Skin Cancers

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

This research report offers invaluable insights into various crucial aspects of the Cancer Biopsy Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Table of Contents
  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. Cancer Biopsy Market, by Product
  7. Cancer Biopsy Market, by Type
  8. Cancer Biopsy Market, by Indication
  9. Americas Cancer Biopsy Market
  10. Asia-Pacific Cancer Biopsy Market
  11. Europe, Middle East & Africa Cancer Biopsy Market
  12. Competitive Landscape
  13. Competitive Portfolio
  14. List of Figures [Total: 22]
  15. List of Tables [Total: 476]
  16. List of Companies Mentioned [Total: 25]
Frequently Asked Questions
  1. How big is the Cancer Biopsy Market?
    Ans. The Global Cancer Biopsy Market size was estimated at USD 29.84 billion in 2023 and expected to reach USD 33.48 billion in 2024.
  2. What is the Cancer Biopsy Market growth?
    Ans. The Global Cancer Biopsy Market to grow USD 67.14 billion by 2030, at a CAGR of 12.28%
  3. When do I get the report?
    Ans. Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
  4. In what format does this report get delivered to me?
    Ans. We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
  5. How long has 360iResearch been around?
    Ans. We are approaching our 7th anniversary in 2024!
  6. What if I have a question about your reports?
    Ans. Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
  7. Can I share this report with my team?
    Ans. Absolutely yes, with the purchase of additional user licenses.
  8. Can I use your research in my presentation?
    Ans. Absolutely yes, so long as the 360iResearch cited correctly.